Products and Projects

Cancer diagnostic tests

Utilizing innovative methods, DiagnoCure is focused on the development and commercialization of molecular tests for the detection and management of cancer.

The following table shows the Company’s main products and projects.

* ASR (Analyte Specific Reagent): Commercialization of test components for sale by reference laboratories under their label and responsibility with an FDA allowance.

** IVD (In Vitro Diagnostic): Commercialization of the test for direct sale by DiagnoCure and/or its partners with an FDA approval.

DiagnoCure holds the ISO 13485 certification for medical devices. DiagnoCure's quality system is audited every year by a Canadian Medical Devices Conformity Assessment System (CMDCAS)-recognized registrar to ensure that the quality system complies with the ISO 13485 and Canadian rules.

Therapeutic applications

DiagnoCure’s strategy for technologies with therapeutic application is to bring them to the proof of concept stage and then to either develop them through a strategic alliance with a pharmaceutical company, to license them to partners, or to create spin-off companies for their further development.

With outside partners, DiagnoCure has undertaken research projects to determine the therapeutic applications of the prostate cancer specific PCA3 gene for which the Company holds an exclusive world wide license.